Found 2065 with Last Name = 'fleming' and Initial = 'p' TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: <0.5nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: <0.5nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: <0.5nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 0.600nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 0.600nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 0.700nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 1nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
Affinity DataIC50: <1nMT: 2°CAssay Description:The reactions (25 μL) were carried out in 25 mM Tris-HCl pH 8.0, 10 mM ammonium sulfate, 1.25 mM DTT, 0.002% Brij-35, 10 mM MgCl2, 40 μM UN...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 1.20nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 1.20nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 1.20nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 1.20nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 1.30nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of Staphylococcus aureus DNA gyrase B expressed in Escherichia coli BL21(DE3) cells assessed ATP hydrolysis activity after 18 to 24 hrs by...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 2nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMT: 2°CAssay Description:The reactions (25 μL) were carried out in 25 mM Tris-HCl pH 8.0, 10 mM ammonium sulfate, 1.25 mM DTT, 0.002% Brij-35, 10 mM MgCl2, 40 μM UN...More data for this Ligand-Target Pair
TargetPhenylalanine--tRNA ligase alpha/beta subunit(Escherichia coli (Enterobacteria))
Astrazeneca R&D Boston
Astrazeneca R&D Boston
Affinity DataIC50: 2.20nMpH: 8.0Assay Description:Compounds were solubilized in DMSO. Serial 2-fold dilutions covering two concentration ranges, 10 mM to 19.5 μM and 100 μM to 195 nM, were ...More data for this Ligand-Target Pair
TargetPhenylalanine--tRNA ligase alpha/beta subunit(Escherichia coli (Enterobacteria))
Astrazeneca R&D Boston
Astrazeneca R&D Boston
Affinity DataIC50: 2.70nMpH: 8.0Assay Description:Compounds were solubilized in DMSO. Serial 2-fold dilutions covering two concentration ranges, 10 mM to 19.5 μM and 100 μM to 195 nM, were ...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMT: 2°CAssay Description:The reactions (25 μL) were carried out in 25 mM Tris-HCl pH 8.0, 10 mM ammonium sulfate, 1.25 mM DTT, 0.002% Brij-35, 10 mM MgCl2, 40 μM UN...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMT: 2°CAssay Description:The reactions (25 μL) were carried out in 25 mM Tris-HCl pH 8.0, 10 mM ammonium sulfate, 1.25 mM DTT, 0.002% Brij-35, 10 mM MgCl2, 40 μM UN...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 4nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of Staphylococcus aureus DNA gyrase B expressed in Escherichia coli BL21(DE3) cells assessed ATP hydrolysis activity after 18 to 24 hrs by...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMT: 2°CAssay Description:The reactions (25 μL) were carried out in 25 mM Tris-HCl pH 8.0, 10 mM ammonium sulfate, 1.25 mM DTT, 0.002% Brij-35, 10 mM MgCl2, 40 μM UN...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMT: 2°CAssay Description:The reactions (25 μL) were carried out in 25 mM Tris-HCl pH 8.0, 10 mM ammonium sulfate, 1.25 mM DTT, 0.002% Brij-35, 10 mM MgCl2, 40 μM UN...More data for this Ligand-Target Pair
Affinity DataIC50: <5nMT: 2°CAssay Description:The reactions (25 μL) were carried out in 25 mM Tris-HCl pH 8.0, 10 mM ammonium sulfate, 1.25 mM DTT, 0.002% Brij-35, 10 mM MgCl2, 40 μM UN...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 5nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMT: 2°CAssay Description:The reactions (25 μL) were carried out in 25 mM Tris-HCl pH 8.0, 10 mM ammonium sulfate, 1.25 mM DTT, 0.002% Brij-35, 10 mM MgCl2, 40 μM UN...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of Staphylococcus aureus DNA gyrase B expressed in Escherichia coli BL21(DE3) cells assessed ATP hydrolysis activity after 18 to 24 hrs by...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 5.10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 5.10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 5.10nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 6nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 7nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 7nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 7.90nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 7.90nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 7.90nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 8nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 8nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 8nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 8nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
TargetUDP-N-acetylmuramate--L-alanine ligase(Pseudomonas aeruginosa (G-proteobacteria))
Astrazeneca India
Astrazeneca India
Affinity DataIC50: 9nMT: 2°CAssay Description:The reactions (50 μL) were carried out in 50 mM Tris-HCl pH 8.0, 20 mM ammonium sulfate, 2.5 mM DTT, 0.002% Brij-35, 1 mM MgCl2, 18 μM UNAM...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of Staphylococcus aureus DNA gyrase B expressed in Escherichia coli BL21(DE3) cells assessed ATP hydrolysis activity after 18 to 24 hrs by...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEP...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
